- Trial phase
- Approved (accelerated approval)
- Time to market
- Already approved and commercially launched in the U.S. (March 2026). Global regulatory submissions are expected to follow the ongoing Phase 2/3 COMPASS confirmatory trial.
- Why 4/10
- Avlayah is already FDA-approved and commercially launched with no pending regulatory decision; the next hard catalyst is the Q3 2026 earnings report on November 4, 2026 (a commercial update, not a binary regulatory event), and the confirmatory COMPASS trial readout has no announced date, so the impactScore is capped at 4 per the rubric for approved drugs with no imminent binary.
The next near-term catalyst is Denali's Q3 2026 earnings report on November 4, 2026, where management's Q3 Avlayah revenue (guided $10-12M, up from $3.6M in Q2) will be the key commercial proof point. The longer-term binary is the confirmatory Phase 2/3 COMPASS trial readout, which will determine whether the accelerated approval converts to full approval, though no specific readout date has been announced.
Price Chart
Executive Summary
Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) received FDA accelerated approval on March 25, 2026 for neurologic manifestations of Hunter syndrome (MPS II), becoming the first approved therapy that crosses the blood-brain barrier for this rare pediatric disease. The drug generated $3.6M in net product revenue in its first full commercial quarter (Q2 2026), beating analyst estimates, with management guiding Q3 2026 to $10-12M. Denali has a strong balance sheet (over $1.1B pro forma cash) and a broad pipeline including Sanfilippo syndrome and Alzheimer's programs. However, the approval is conditional on confirmatory data from the ongoing Phase 2/3 COMPASS trial, and the stock trades at ~$19, well below the $35.50 mean analyst target, reflecting commercial execution risk and the small addressable market.
How It Works
Avlayah is an enzyme replacement therapy for Hunter syndrome, a rare genetic disorder where the body cannot break down certain sugars, causing damage to organs and the brain. The drug delivers a missing enzyme (iduronate 2-sulfatase) fused to a special 'transport vehicle' that allows it to cross the blood-brain barrier, which no previous Hunter syndrome treatment could do. It is given as a weekly intravenous infusion.
Trial Status
Approval was based on a Phase 1/2 open-label trial (47 patients) showing a 91% average reduction in CSF heparan sulfate (biomarker) by Week 24, with 93% of patients reaching normal levels. The ongoing global Phase 2/3 COMPASS trial (NCT05371613) is the confirmatory study required to convert accelerated approval to full approval.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings report on November 4, 2026, with Avlayah revenue expected to be $10-12M (up from $3.6M in Q2)
- Phase 2/3 COMPASS confirmatory trial readout (date not yet announced)
- Potential global regulatory submissions (ex-U.S.) based on COMPASS data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Denali Therapeutics Inc. Press Release DNLI ·Originating report